Clinical Trials Logo

NTRK Family Gene Mutation clinical trials

View clinical trials related to NTRK Family Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT04921553 Recruiting - Cancer Clinical Trials

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

TRacKING
Start date: June 22, 2021
Phase:
Study type: Observational [Patient Registry]

This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion. This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications.

NCT ID: NCT04557813 Active, not recruiting - Clinical trials for NTRK Family Gene Mutation

Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion

REALTRK
Start date: December 2, 2020
Phase:
Study type: Observational [Patient Registry]

The objective of this registry is to analyze treatment reality and outcome of patients with locally advanced or metastatic solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3

NCT ID: NCT03994796 Recruiting - Clinical trials for Metastatic Malignant Solid Neoplasm

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Start date: August 15, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.